risankizumab
abbvie
['crohn', 'ibd']
ferrante - risa (anti-p19) effective in the more difficult to treat #crohnsdisease after failure of multiple biologics; dose-response in patients with higher number of prior biologics: 360 mg&gt;180 mg&gt;pbo for maintenance and endoscopic endpoints #uegweek22 #ibd
Swedish physician specializing in the treatment of Crohn's disease and Ulcerative Colitis. Views - my own.